" class="no-js "lang="en-US"> Steven Albelda - Medtech Alert
Thursday, September 04, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Steven Albelda

Steven Albelda

About Steven Albelda

Member, Penn Abramson Cancer Center
Co-Director, Thoracic Oncology Research Laboratory, University of Pennsylvania
Director of Lung Research, Pulmonary, Allergy, and Critical Care, University of Pennsylvania
Founding Member, Center for Cancer Pharmacology
Co-Director. Translational Center of Excellence in Lung Cancer, Abramson Cancer Center

Related Story

Diseases

 Philadelphia-based Biotech Company AUM LifeTech Awarded $400

Philadelphia-based Biotech Company AUM LifeTech Awarded $400,000 NCI/NIH Grant to Advance Their Lung Cancer Immunotherapy Program Using RNA-Targeting Gene Therapy with Checkpoint Inhibitors

August 18 2022

AUM LifeTech, Inc., a Philadelphia-based preclinical stage biotechnology company, has received a Small Business Innovation Research […]